The NHS is both the UK's most loved institution and one of its most contested policy questions. It consumes £345 billion a year — more than any other government programme. Yet outcomes in cancer survival, heart disease and treatable mortality consistently rank in the lower half of comparable nations. This page examines the spending data, the productivity record, the international comparisons, and the honest evidence on where the NHS over- and under-delivers.
The Money — How Much, Where It Goes, and Is It Enough?
The UK spent approximately £345 billion on healthcare in 2025 — including both NHS and private spending. This is equivalent to 11.4% of GDP and approximately £4,966 per person per year. The NHS itself accounts for the large majority of this — NHS England's budget alone is £182 billion.
These are large numbers in absolute terms, but context matters. Between 2010 and 2019 — the decade of austerity — average day-to-day UK health spending was £3,005 per person per year, which was 18% below the EU-14 average of £3,655. The NHS Confederation calculated that if the UK had matched EU-14 peers on per-capita spending across that decade, total additional spending would have been £40 billion per year — and NHS output (measured by hospital episodes) would have been 41% higher.
The capital investment gap was even larger. UK healthcare capital investment (buildings, machinery, IT, equipment) as a share of GDP has been below the EU-14 average throughout the past decade. Across 2010-2019, the UK would have needed to invest an additional £33 billion in healthcare capital to match EU-14 peers. The maintenance backlog — the accumulated cost of deferred repairs and upgrades — has risen to £16 billion for NHS England alone, with essential backlog growing from under £5 billion in 2015/16 to £10.2 billion by 2021/22.
International Comparison — How the NHS Compares to European Systems
The NHS is frequently described as the envy of the world — a claim that requires some unpacking. The NHS genuinely does excel at administrative efficiency: because it does not have to deal with billing between dozens of insurance companies, administrative costs are far lower than in insurance-based systems. In "macro-efficiency" terms — getting a lot done for the budget spent — the NHS performs well.
But in outcomes — the health results actually achieved — the picture is more mixed.
| Country | System Type | Spend Per Capita (USD) | Treatable Mortality (per 100k) | Cancer 5yr Survival | Waiting Lists |
|---|---|---|---|---|---|
| 🇬🇧 UK (NHS) | Single payer/public | $4,653 | 71 | ~50-55% | Very Long |
| 🇩🇪 Germany | Social insurance | $7,383 | 51 | ~60-65% | Short |
| 🇫🇷 France | Social insurance | $5,468 | 52 | ~58-63% | Short |
| 🇳🇱 Netherlands | Regulated insurance | $6,753 | 44 | ~62-67% | Short |
| 🇸🇪 Sweden | Regional public | $6,262 | 38 | ~64-68% | Medium |
| 🇨🇭 Switzerland | Regulated insurance | $9,666 | 40 | ~64-68% | Short |
| OECD Average | Mixed | $5,071 | 77 | ~55-60% | Medium |
The treatable mortality figure is the starkest outcome comparison. This measures deaths that could have been avoided through timely, effective healthcare. The UK's rate of 71 per 100,000 is better than the OECD average of 77 — but significantly worse than the Netherlands (44) or Sweden (38). Research indicates that if the UK could match Sweden's survival rates, over 25,000 additional lives would be saved every year.
What explains the gap? Multiple factors:
Early diagnosis: In insurance-based systems, diagnostic tools (MRI, CT scans) are more plentiful. In the UK, late diagnosis is a persistent issue — GP gatekeeping and long imaging waitlists mean conditions are often caught later. This is particularly significant in cancer, where the difference between early and late diagnosis is literally life and death.
Bed capacity: The UK has 2.5 hospital beds per 1,000 people — less than half the OECD average of 5.5 and well below Germany's 8.0. This structural shortage means patients wait longer for procedures and are more likely to be treated in deteriorating condition.
GP model: The NHS uses GPs as gatekeepers to specialist care — a model that manages demand but creates bottlenecks. In Germany and France, patients can access specialists more directly, reducing delays.
NHS Productivity — The Post-Pandemic Problem
NHS productivity is currently one of the most actively monitored topics in UK health policy. The 2025 Spending Review explicitly set a 2% annual productivity improvement target — recognition that funding alone is insufficient and that the NHS must do more with what it receives.
NHS England now publishes monthly trust-level productivity statistics from February 2026 — a significant step towards accountability. The overall productivity picture is mixed: NHS acute productivity has delivered an average of approximately 2% annual improvement over the last three years, suggesting the 2% target is achievable. But acute productivity improvement has been partially offset by non-acute sector underperformance.
The 170 Community Diagnostic Centres rolled out since 2022 are one concrete productivity success — delivering 6.8 million additional tests in 2024/25 and supporting an 8% improvement in theatre utilisation. The Federated Data Platform has helped 71 trusts reduce waiting lists by an average of 11%.
The waiting list picture has genuinely improved at the extremes. Patients waiting over 65 weeks fell 84.9% between March 2024 and March 2025 — from 48,967 to 7,381. The proportion of patients waiting over 52 weeks is targeted to fall below 1% of the total list by March 2026. However, the total waiting list — patients waiting for any treatment — remains stubbornly high and the NHS has not yet achieved the 2019 targets the government inherited.
The RAAC Crisis and the Capital Backlog
Reinforced Autoclaved Aerated Concrete — a lightweight building material used extensively in NHS hospitals between the 1960s and 1980s — has a design lifespan of 30 years. Many NHS buildings containing it are now 40-60 years old. When the risk was first formally identified in 1996, no systematic checks were initiated. Systematic inspection did not begin until 2022.
By mid-2026, 47 hospital sites in England have confirmed RAAC. In some hospitals, ceilings are being held up by temporary jack posts. The government allocated £440 million in 2025/26 alone to address the problem, with seven hospitals having eradicated RAAC completely and 12 more expected to be RAAC-free by March 2026. Around 50% of affected hospitals have removed or are removing RAAC — but the remaining half continue to operate in buildings that are structurally compromised.
The RAAC issue is symptomatic of a broader failure of NHS capital investment. The total maintenance backlog across all NHS England buildings reached nearly £16 billion in 2025 — up from a much lower base a decade ago. The National Audit Office specifically warned that allowing large maintenance backlogs to build up was a "false economy" — deferred maintenance costs significantly more to address later than to prevent.
The Private Sector Trend — What Increasing Privatisation Tells Us
Out-of-pocket and private health spending in the UK reached £48.5 billion in 2025 — 14.1% of total health expenditure, and significantly higher than a decade ago. This rise reflects increasing numbers of people paying for private diagnosis and treatment to bypass NHS waiting lists.
This trend has fiscal consequences that are rarely discussed. When wealthier patients exit the NHS waiting list by paying privately, they reduce political pressure to fix the system — since those with the most political voice no longer have a personal stake in NHS performance. Simultaneously, NHS income from those patients who would have been treated (and whose treatment would have contributed to productivity metrics) is lost.
The private sector also draws on the same pool of trained doctors and nurses — staff who are often doing NHS work in their contracted hours and private work in additional hours. Some evidence suggests this reduces NHS productivity at the margin, though it also provides additional income that helps retain clinical staff who might otherwise leave.